CONTEXT
LBCL, B-cell lymphoma
ADVERSE EVENT, B-CELL LYMPHOMA, CYTOKINE RELEASE SYNDROME


Outcomes are poor for patients with relapsed or refractory large B-cell lymphoma (LBCL). This study evaluated the efficacy and safety of subcutaneous epcoritamab, a bispecific antibody targeting CD3 and CD20, in a dose-expansion cohort of patients with relapsed or refractory LBCL.
Single-agent epcoritamab demonstrated high overall response rates, including deep and durable complete responses. Adverse events were manageable, with few discontinuations; cytokine release syndrome was mostly low grade with predictable timing.
The observed high response rates with durability in patients with refractory LBCL treated with epcoritamab, including post–chimeric antigen receptor-T therapy, represent further evidence of the value of bispecific antibodies in this setting. Future studies need to evaluate feasibility of limited duration therapy, explore rational combinations, and incorporate this agent into earlier lines of treatment.**Relevance section written by Epcoritamab (GEN3013) is a subcutaneously administered, bispecific antibody targeting CD3 and CD20 that redirects and activates T cells to kill CD20-expressing malignant cells.